1. Preventing Clinical Events in PAH

2. Elaine, a Young Patient With Advanced Symptoms

3. Further Examination Reveals Signs of PH

4. Confirming the Diagnosis

5. Initial Risk Assessment Determines Initial Treatment

6. Treatment Options in PAH

7. Increasing Use of Combination Therapy

8. AMBITION Trial: Confirmed Benefit of Upfront Combination Therapy

9. When to Add Prostanoid Therapy?*

10. Continuously Reassess and Get Patient to Goal

11. Elaine Improves on Dual Combination Therapy

12. Next Steps for Low-Risk Patient?

13. Importance of Thinking About the Future of Individual Patients
Importance of Thinking About the Future of Individual Patients NOT the Past

14. GRIPHON: Adding Selexipag as Third Therapy

15. GRIPHON: Improving Long-Term Outcomes With a More Aggressive Approach

16. Watch Closely and Take Action if Condition Deteriorates

17. Next Steps for High-Risk Patient?

18. Hospitalization Portends Worse Outcome

19. Morbidity Events in SERAPHIN and GRIPHON

20. SERAPHIN Month 3 Landmark: Association Between Morbidity Before Month 3 and Mortality

21. SERAPHIN: Association Between Morbidity and Mortality at Any Landmark Timepoint*

22. GRIPHON Month 3 Landmark: Association Between Morbidity Before Month 3 and Mortality

23. GRIPHON: Association Between Morbidity and Mortality at Any Landmark Time Point*

24. GRIPHON: Association Between Individual Morbidity Components and Mortality

25. Achieving Low-Risk Status in PAH

26. Registry Data Confirm Need for Early Diagnosis and Treatment Intensification

27. Conclusion

28. Abbreviations

29. Abbreviations (cont)